Z. Adam
The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention
Adam, Z.; Turley, A.; Mason, J.M.; Kasim, A.S.; Newby, D.; Mills, N.; Padfield, G.; Thompson, L.; Morley, R.; Hall, J.A.; Wright, R.A.; Muir, D.F.; Sutton, A.G.C.; Swanson, N.; Carter, J.; Bilous, R.; Jones, S.; de Belder, M.A.
Authors
A. Turley
J.M. Mason
A.S. Kasim
D. Newby
N. Mills
G. Padfield
L. Thompson
R. Morley
J.A. Hall
R.A. Wright
D.F. Muir
A.G.C. Sutton
N. Swanson
J. Carter
R. Bilous
S. Jones
M.A. de Belder
Abstract
Background Stent design and technological modifications to allow for anti-proliferative drug elution influence restenosis rates following percutaneous coronary intervention (PCI). We aimed to investigate whether peri-procedural administration of corticosteroids or the use of thinner strut cobalt alloy stents would reduce rates of binary angiographic restenosis (BAR) after PCI. Methods This was a two centre, mixed single and double blinded, randomised controlled trial using a factorial design. We compared (a) the use of prednisolone to placebo, starting at least six hours pre-PCI and continued for 28 days post-PCI, and (b) cobalt chromium (CoCr) to stainless steel (SS) alloy stents, in patients admitted for PCI. The primary end-point was BAR at six months. Results 315 patients (359 lesions) were randomly assigned to either placebo (n = 145) or prednisolone (n = 170) and SS (n = 160) or CoCr (n = 160). The majority (58%) presented with an ACS, 11% had diabetes and 287 (91%) completed angiographic follow up. BAR occurred in 26 cases in the placebo group (19.7%) versus 31 cases in the prednisolone group (20.0%) respectively, p = 1.00. For the comparison between SS and CoCr stents, BAR occurred in 32 patients (21.6%) versus 25 patients (18.0%) respectively, p = 0.46. Conclusion Our study showed that treating patients with a moderately high dose of prednisolone for 28 days following PCI with BMS did not reduce the incidence of BAR. In addition, we showed no significant reduction in 6 month restenosis rates with stents composed of CoCr alloy compared to SS (http://www.isrctn.com/ISRCTN05886349).
Citation
Adam, Z., Turley, A., Mason, J., Kasim, A., Newby, D., Mills, N., …de Belder, M. (2016). The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention. International Journal of Cardiology, 216, 1-8. https://doi.org/10.1016/j.ijcard.2016.04.105
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 11, 2016 |
Online Publication Date | Apr 29, 2016 |
Publication Date | Aug 1, 2016 |
Deposit Date | May 23, 2017 |
Publicly Available Date | Mar 29, 2024 |
Journal | International Journal of Cardiology |
Print ISSN | 0167-5273 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 216 |
Pages | 1-8 |
DOI | https://doi.org/10.1016/j.ijcard.2016.04.105 |
Related Public URLs | http://wrap.warwick.ac.uk/79375/ |
Files
Accepted Journal Article
(1.3 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright Statement
© 2016 This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Multisite educational trials: estimating the effect size and its confidence intervals
(2021)
Journal Article
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search